NorthWest Biotherapeutics Inc (NWBO)

[abeta]

You kinda said .....

M+ == pro-neural
M- == mesenchymal(MES), classical and neural.
M+ is not as aggressive as M-

If the abstract cited is accurate, this bodes extremely well for DC VAX as it appears to be very efficacious
for M+(pro-neural and 40% of trial ITT and 45% of overall categorised group--N=293) and a significant
percentage of M- due to MES. This would cover at least 50% of all ndGBM!

I was kinda gonna shoot back that this -- very efficacious
for M+(pro-neural and 40% of trial ITT -- can't be right as the % too high ......

So I set out to get the graphs to prove it ......

Then bumped into this 2019 ditty .....

https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=6520485_41598_2019_43173_Fig2_HTML.jpg


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520485/

I was wrong - again -

anyway